IL6 and infection: Of note it is important to aggressively treat the underlying condition with additional specific therapies: chemotherapy for malignancies, rituximab for EBV-associated HLH, IVIG and antimicrobials for infections, anti-interleukin 1 for HLH associated with autoimmune diseases, and anti-interleukin 6 in HLH secondary to immune checkpoint inhibitors/chimeric antigen T cells [3,61].